FerroptoCure develops therapeutic drugs that utilize ferroptosis to create targeted anticancer therapies for patients with cancer. The company aims to provide effective treatment options based on scientific evidence, addressing the need for more effective cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing therapies, and new treatment strategies are needed to overcome this resistance and improve patient outcomes. Current cancer treatments may not effectively target the underlying mechanisms that allow cancer cells to survive and proliferate.
Solution
FerroptoCure is developing a new class of anticancer drugs that induce ferroptosis, an iron-dependent form of cell death, in cancer cells. The company's pipeline focuses on disrupting the mechanisms that cancer cells use to suppress ferroptosis, particularly in cancers that have developed resistance to other treatments. By targeting these resistance mechanisms, FerroptoCure aims to create therapies that can effectively eliminate cancer cells and prevent disease progression. Their approach involves using next-generation sequencing, data informatics, and in silico analysis, along with collaborative research with universities and other research institutions.
Target Audience
The primary target audience includes cancer patients who have developed resistance to existing therapies, as well as veterinary professionals seeking novel cancer treatments for pets.
Features
- Focus on inhibiting xCT, a cystine-glutamate transporter subunit, to induce ferroptosis.
- Development of therapies to overcome resistance mechanisms to xCT inhibitors.
- Pipeline includes drugs applicable to both human and animal (pet) cancers.
- Aims to develop highly safe drugs suitable for use in both humans and pets.